Pfizer's unexpected deal with the Trump administration on drug pricing sends shockwaves through the pharmaceutical industry, pressuring competitors to follow suit amidst potential regulatory threats. What’s next for drug prices?
Eli Lilly announces a groundbreaking $5 billion investment in a new manufacturing plant near Richmond, aimed at boosting U.S. production of essential pharmaceutical ingredients.
In a day marked by significant market movements, EchoStar's stock skyrocketed following AT&T's $23 billion purchase of wireless licenses. Eli Lilly also saw gains with promising diabetes drug results, while Nvidia's upcoming report looms large.
Lilly's new oral pill, Orforglipron, has shown promising results in reducing weight and improving blood sugar levels in diabetes patients. With nearly 4% rise in shares, the drug is on track for FDA approval.
Eli Lilly's new obesity pill, orforglipron, faces tough competition but could disrupt the weight loss market. Despite underwhelming trial results, analysts see potential for success due to manufacturing advantages and pricing strategies.
Eli Lilly announces a dramatic price increase for its diabetes medication Mounjaro in the UK, raising the monthly cost from £122 to £330. This change affects private buyers but not NHS prescriptions. Learn more about the implications!
In a surprising move, Novo Nordisk CEO Lars Fruergaard Jorgensen steps down as the company faces significant market challenges and competition from Eli Lilly's Zepbound. With share prices plummeting, the board seeks new leadership to navigate the turbulent landscape.
Pfizer Inc. has decided to stop the development of its obesity pill, danuglipron, after safety concerns emerged from a clinical trial. This move comes as competition heats up with Novo Nordisk and Eli Lilly's successful weight-loss treatments.
Eli Lilly is set to unveil results from trials of orforglipron, its groundbreaking once-daily obesity pill, potentially revolutionizing weight loss treatment by offering a needle-free alternative. Analysts predict it could capture a significant share of the $150 billion GLP-1 market.
Discover how women like Elizabeth Lilly and others are transforming family offices, taking on key investment roles, and showcasing a more conservative approach to wealth management.
